DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

DVA·DaVita Inc.

$.
+. (+.%)
After Hours
High
$235.00
Open
$230.91
Market Cap
14.95B
52W High
$239.64
Low
$228.43
P. Close
$232.80
P/E
19.13
52W Low
$101.00
Fwd P/E
13.52
DailyIQ Est.
$198.56
Technical Score (1D)
86
BUY
News Sentiment
87
BULLISH
Analysts now forecast Q2 EPS of $4.01, up 35.93% YoY, implying stronger earnings momentum that could support a rally; watch the upcoming earnings release for confirmation. UBS projects a return to 2% volume growth by 2029 if Medicare reimbursement stabilizes, which could lift margins; watch Medicare reimbursement policy updates. UBS upgraded DVA to Buy and raised its target to $270, reflecting confidence in the earnings outlook; watch for any regulatory changes that could affect dialysis demand. Barclays lifted its price target to $218 and kept an equal‑weight rating, signaling optimism about margin expansion; watch for earnings guidance and reimbursement developments. DaVita is adding AI‑driven scheduling to its Integrated Kidney Care platform to improve care coordination and operational efficiency, which could enhance margins; watch operational metrics in the next earnings. Zacks added DVA to its Rank #1 growth list, boosting analyst confidence; watch for any changes in growth guidance. DCF analysis indicates a 19% premium over market multiples, raising valuation concerns; watch for any valuation adjustments in the next earnings. Despite a strong monthly gain, DVA closed 1.53% lower than the market, indicating potential short‑term volatility; watch intraday trading for support levels. Berkshire Hathaway’s long‑term stake and recent Weschler selection reinforce a defensive view of DVA’s dialysis model; watch for any changes in Berkshire’s ownership or capital allocation decisions.
Earnings Summary
DaVita Inc. is a leading provider of kidney dialysis services in the United States, operating outpatient dialysis centers and offering inpatient, home‑based, and laboratory services as part of a comprehensive kidney‑care platform. The company’s business is anchored in the medical‑care‑facilities sector, where reimbursement dynamics and patient volume drive performance. In the most recent quarters, DaVita’s Q4 2024 earnings surpassed expectations with an EPS of $2.24 versus a $2.13 estimate and revenue of $3.295 billion, while Q1 2025 saw a modest EPS miss at $2.00 against a $2.02 estimate and revenue of $3.224 billion; Q2 2025 reversed the trend with an EPS of $2.95 beating a $2.75 estimate and revenue of $3.380 billion, but Q3 2025 recorded an EPS of $2.51 below a $3.17 estimate despite revenue of $3.420 billion; Q1 2026 again beat expectations with an EPS of $2.87 versus $2.33 and revenue of $3.416 billion versus a $3.356 billion estimate. Over the past year, revenue has fluctuated, rising from $3.295 billion in Q4 2024 to $3.420 billion in Q3 2025 before settling near $3.416 billion in Q1 2026, while EPS has oscillated between $2.00 and $2.95, indicating a pattern of earnings volatility amid steady revenue growth. Recent news highlights a Barclays price‑target upgrade to $218, a Zacks Rank #1 growth designation, and the rollout of AI‑driven scheduling tools that could enhance operational efficiency; these developments underscore market confidence in DaVita’s growth trajectory and potential margin improvement. Investors should watch for the Q2 2026 earnings release to confirm guidance, monitor regulatory updates that could affect Medicare reimbursement rates, and assess the pace of AI tool deployment, as these factors will be key to sustaining the company’s earnings momentum.

EPS

EstBeatMiss
$1.72$2.33$2.94$3.55$4.16Q4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.88 - -
Q1'26$2.33$2.87+23.2%
Q3'25$3.17$2.51-20.9%
Q2'25$2.75$2.95+7.3%
Q1'25$2.02$2.00-1.0%
Q4'24$2.13$2.24+5.4%

Revenue

EstBeatMiss
$3.2B$3.3B$3.4B$3.5B$3.6BQ4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.5B - -
Q1'26$3.4B$3.4B+1.8%
Q3'25 - $3.4B -
Q2'25 - $3.4B -
Q1'25 - $3.2B -
Q4'24 - $3.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DVA Stock Snapshot

DVA is currently trading at $235.00, giving DaVita Inc. a market cap of 14.95B and a P/E ratio of 19.1. Today's range spans $228.43–$235.00, with shares opening at $230.91 and moving up $2.20 (0.9%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 87/100.

Over the past year DVA has traded between $101.00 and $239.64 - the current price is +132.7% off the 52-week low and -1.9% from the high. 14 analysts cover the stock with a Hold consensus and a mean 12-month target of $197.14 (range $145.00–$235.00), implying downside of -16.1%.

DVA is scoring 86/100 technically (BUY) and sits at $235.00 - near 52-week highs in its $101.00–$239.64 annual range. Sentiment at 87/100 is bullish. At 14.95B in Healthcare market cap The current P/E ratio stands at 19.1., this is the tier where earnings revision cycles have the most impact on price: upward revisions in a large-cap company with bullish momentum tend to attract analyst upgrades, which in turn attract new institutional mandates.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (87/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $235.00 (near 52-week highs), DVA's position within the $101.00–$239.64 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.